The UK government has issued a serious warning concerning the use of the weight-loss drug Mounjaro, particularly for women, just as the medication is set to be introduced on the National Health Service (NHS) starting 23 June. Previously available only through private prescriptions in the UK, Mounjaro will now be offered as a treatment for weight management on the NHS.
Mounjaro, originally developed for the treatment of Type 2 diabetes, has increasingly gained attention for its weight loss effects. It works by mimicking the body’s GLP-1 and GIP hormones, which are released after eating and help users feel fuller for longer, thereby reducing appetite. When used alongside a healthy diet and regular physical activity, the drug has shown notable health benefits for those eligible.
Despite its benefits, the Medicines and Healthcare products Regulatory Agency (MHRA) has advised caution, especially for women who are pregnant, breastfeeding, or planning to become pregnant. The agency warned that there is insufficient safety data to confirm whether Mounjaro could harm an unborn child. Therefore, any woman who becomes pregnant while taking the drug should stop immediately and consult a healthcare provider.
The MHRA also stated that Mounjaro might reduce the effectiveness of oral contraceptives in women who are overweight. As a precaution, the agency recommends using an additional non-oral contraceptive method, such as an implant, intrauterine device (IUD), injectable birth control, or barrier methods like condoms. This is particularly important during the first four weeks after starting the drug or following any dose increase.
Access to Mounjaro through the NHS is expected to be limited, with up to 220,000 people projected to receive it over the next three years. Oliver Picard, chair of the National Pharmacy Association, said the NHS will not be able to meet the full demand immediately, noting that many general practitioners lack the resources to provide the level of support needed. As a result, many patients may continue to seek the medication privately.
The drug’s manufacturer, Eli Lilly and Company, emphasized its commitment to patient safety and acknowledged that Mounjaro may affect the absorption rate of oral medications, especially at the start of treatment. The company advises women using oral contraceptives and who are overweight to consider switching to or adding another form of birth control for four weeks after beginning treatment and after each dosage increase.
Healthcare professionals stress that GLP-1 medications like Mounjaro should only be taken under medical supervision and with a valid prescription. The MHRA’s guidance is also included in the patient information leaflets provided with the medication, ensuring that individuals are fully informed about potential risks and necessary precautions.
Related Topics:
